App-Quantinova.ai

Extensive thrombosis from cranial venous sinuses to superior vena cava in an infant with Lemierre syndrome with successful management

J. Connors - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Factors Associated with Anticoagulant Treatment Initiation Among Venous Thromboembolism Patients with Cancer

S. Shah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Focused on cerebral venous thrombosis

S. Herrero Martin - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation

D. Stegner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Frequency of Factor II, Factor V Leiden and MTHFR mutations in children with cancer

J. Roganovic - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Genetic deletion of Prenylcysteine Oxidase 1 (PCYOX1) impairs arterial thrombosis in mice.

P. Amadio - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Haemostatic differences between SARS-CoV-2 PCR-positive and -negative patients at the time of hospital admission

J. Remijn - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Hand grip strength and risk of incident venous thromboembolism: The Tromsø Study

O. Leknessund - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Hepsin is a risk factor for thrombosis and metastasis in localized colorectal cancer patients

D. Zaragoza Huesca - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

High factor VIII levels and recurrent thromboembolism in patients with and without inflammatory bowel disease: a retrospective comparative study

S. Schulman - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

FVIII

High plasma levels of C1 esterase inhibitor reduce intrinsic pathway-initiated coagulation and are associated with reduced future risk of venous thromboembolism

S. Grover - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Evithrom

High rate of recurrent thrombosis in children with unprovoked venous thromboembolism

H. Whitworth - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Homocysteine as an independent thrombosis risk factor

G. Sottilotta - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Protein C

Hyperinflammatory state and death in patients affected by COVID-19: role of vaccines.

L. Marchini - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Identification of risk factors for major bleeding during anticoagulation and recurrent venous thromboembolism after its discontinuation in patients with a first unprovoked venous thromboembolism.

C. Gabara - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impact of Age-adjusted International Prognostic Index for Predicting Venous Thromboembolism in Thai Patients with Diffuse Large B-cell Lymphoma

N. Hantrakun - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impact of COVID-19 pandemic on VTE investigation and diagnosis rate in Belfast Health and Social Care Trust, Northern Ireland.

N. Sotiropoulou - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impact of thrombophilia testing on treatment decision and outcome of thromboembolism and pregnancy morbidity: a single center retrospective cohort study

K. Vrotniakaite-Bajerciene - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impact of venous thromboembolism on physical functioning: Results from a prospective cohort study

D. Steiner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Impaired platelet function caused by Vibrio cholera outer membrane vesicles

W. Schrottmaier - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Filters

7277 Abstracts